Should I Buy LTRN? LTRN 2026 Analysis

Should You Buy Lantern Pharma Inc (LTRN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.110

1 Day change

-1.89%

52 Week Range

5.740

Analysis Updated At

2026/01/26

Lantern Pharma Inc (LTRN) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock shows no significant positive catalysts, weak financial performance, and a high probability of further decline in the short to medium term. A hold strategy is recommended until stronger signals or catalysts emerge.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 51.062, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 3.426, with resistance at 3.57 and support at 3.282. Overall, the technical indicators suggest a lack of strong momentum in either direction.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate minimal bearish sentiment, but the low overall volume and open interest suggest limited trading activity and interest in the stock.

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news, insider activity, or hedge fund interest. The AI Stock Picker and SwingMax signals are also absent.

Neutral/Negative Catalysts

The stock has a 90% chance of declining by -0.36% in the next day, -2.52% in the next week, and -21.58% in the next month. Financial performance is weak, with negative net income and EPS trends. No recent congress trading data or significant trading trends from insiders or hedge funds.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop of -7.29% YoY to -$4,177,423, and an EPS decline of -7.14% YoY to -0.39. Gross margin remains at 0%. Overall, the financials indicate poor performance and no growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data is available for LTRN, which limits insights into Wall Street sentiment.

1 Analyst Rating

Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is 25 USD with a low forecast of 25 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.170

Low

Averages

High

Current: 3.170

Low

Averages

High

Lake Street

Chad Messer

Strong Buy

Initiates

$25

AI Analysis

2025-04-02

Reason

Lake Street

Chad Messer

Price Target

$25

AI Analysis

2025-04-02

Initiates

Strong Buy

Reason

Lake Street initiated coverage of Lantern Pharma with a Buy rating and $25 price target. Lantern's Response Algorithm for Drug Positioning and Rescue, or RADR, platform consists of a suite of AI modules designed to help advance cancer drug development, the analyst tells investors. Unlike many biotech AI platform companies, Lantern is monetizing RADR through advancement of its own pipeline of four clinical, plus additional preclinical, stage molecules, though they also engage in collaborations with partners, adds the analyst, who notes that lead clinical program LP-300 targets a unique set of lung cancer patients who never smoked.

LTRN Should I Buy

LTRN Should I Buy

Should You Buy Lantern Pharma Inc (LTRN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch